Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs3731249
rs3731249
0.030 GeneticVariation BEFREE By direct sequencing of polymerase chain reaction (PCR)-amplified microdissected genomic DNA; no somatic or germline p16INK4a point mutations or small deletions were detected in the remaining 34 tumour samples; one individual exhibited the previously described germline codon 148 (Ala-->Thr) polymorphism. 9536218

1998

dbSNP: rs1277299943
rs1277299943
0.010 GeneticVariation BEFREE There were 3 G --> A point mutations in the tumour tissue. 11286481

2001

dbSNP: rs771138120
rs771138120
0.010 GeneticVariation BEFREE The observation that a wide variety of tumors develop in mice harboring the Cdk4(R24C</span>) mutation offers a genetic proof that Cdk4 activation may constitute a central event in the genesis of many types of cancers in addition to melanoma. 11756559

2002

dbSNP: rs1377159790
rs1377159790
0.010 GeneticVariation BEFREE One tumour with a single base deletion in the N-terminus (codon 8) of the CDKN2A/p16(INK4a) gene carried a novel germ-line mutation or a rare polymorphism (Ile51Met) in exon 2 of the CDK4 gene. 11960918

2002

dbSNP: rs104894094
rs104894094
0.010 GeneticVariation BEFREE The G101W founder mutation was detected in 4% of SPC cases but the rate increased to 13% when tumor clustering in either branch of families was taken into account. 14679123

2004

dbSNP: rs1444669684
rs1444669684
0.090 GeneticVariation BEFREE However, we identified a p14ARF exon 1beta missense germline mutation (G16D) in a melanoma-neural system tumour syndrome (CMM+NST) family and a 8474 bp germline deletion from 196 bp upstream of p14ARF exon 1beta initiation codon to 11233 bp upstream of exon 1alpha of p16(INK4A) in a family with five melanoma cases. 15937071

2006

dbSNP: rs1444669684
rs1444669684
0.090 GeneticVariation BEFREE Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. 17349581

2007

dbSNP: rs1289280947
rs1289280947
0.010 GeneticVariation BEFREE The objective of our investigation was to evaluate associations between the MSH6 G39E (116G>A) polymorphism and CpG island methylator phenotype (CIMP) and BRAF V600E mutations in tumors from a sample of 1048 individuals with colon cancer and 1964 controls from Utah, Northern California, and Minnesota. 19582761

2009

dbSNP: rs774904310
rs774904310
0.010 GeneticVariation BEFREE The objective of our investigation was to evaluate associations between the MSH6 G39E (116G>A) polymorphism and CpG island methylator phenotype (CIMP) and BRAF V600E mutations in tumors from a sample of 1048 individuals with colon cancer and 1964 controls from Utah, Northern California, and Minnesota. 19582761

2009

dbSNP: rs1444669684
rs1444669684
0.090 GeneticVariation BEFREE We found that the deletion of Ink4a/Arf in K-Ras(G12D) expressing mice led to high expression of PDGF-D signaling pathway in the tumor and tumor-derived cell line (RInk-1 cells). 22806240

2013

dbSNP: rs1444669684
rs1444669684
0.090 GeneticVariation BEFREE Both tumors develop in mice upon conditional deletion in melanocytes of Ink4a/Arf tumor suppressor genes with concomitant expression of oncogene H-Ras(G12V) and a known tumor antigen. 23173060

2012

dbSNP: rs3088440
rs3088440
0.030 GeneticVariation BEFREE We determined tumor HPV16 status and expression of p14/p53 and genotyped p14 (ARF) -rs3731217 and -rs3088440 polymorphisms in 552 incident SCCOP patients. 24104554

2014

dbSNP: rs3731217
rs3731217
0.010 GeneticVariation BEFREE We determined tumor HPV16 status and expression of p14/p53 and genotyped p14 (ARF) -rs3731217 and -rs3088440 polymorphisms in 552 incident SCCOP patients. 24104554

2014

dbSNP: rs3088440
rs3088440
0.030 GeneticVariation BEFREE We investigated the potential association of two CDKN2A polymorphisms, 500C > G (rs11515) and 540C > T (rs3088440), with cervical neoplasia in patients with cervical lesions and healthy controls (n = 492). 24491138

2014

dbSNP: rs11515
rs11515
0.010 GeneticVariation BEFREE We investigated the potential association of two CDKN2A polymorphisms, 500C > G (rs11515) and 540C > T (rs3088440), with cervical neoplasia in patients with cervical lesions and healthy controls (n = 492). 24491138

2014

dbSNP: rs3731249
rs3731249
0.030 GeneticVariation BEFREE In univariable analysis, tumor stage (log rank P = 0.006) and grade (P < 0.001), HPV DNA (P < 0.004), Chromosome 9 loss (P = 0.04) and the A148T polymorphism (rs 3731249) in CDKN2A (P = 0.02) were associated with progression. 25142434

2014

dbSNP: rs1057519852
rs1057519852
T 0.700 GeneticVariation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014

dbSNP: rs121913381
rs121913381
A 0.700 GeneticVariation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014

dbSNP: rs121913382
rs121913382
A 0.700 GeneticVariation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014

dbSNP: rs121913383
rs121913383
A 0.700 GeneticVariation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014

dbSNP: rs121913384
rs121913384
A 0.700 GeneticVariation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014

dbSNP: rs121913387
rs121913387
A 0.700 GeneticVariation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014

dbSNP: rs121913389
rs121913389
T 0.700 GeneticVariation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014

dbSNP: rs1444669684
rs1444669684
0.090 GeneticVariation BEFREE Orthotopic implantation of PDCs carrying the activated Kras(G12D</span>)-allele and shRNA against p16(Ink4a) or Trp53 resulted in tumor growth, metastasis, and reduced survival of NSG mice. 25724428

2015

dbSNP: rs1444669684
rs1444669684
0.090 GeneticVariation BEFREE Coactivation of BRAF(V600E) and KRAS(G12D) markedly reduced lung tumor numbers and overall tumo</span>r burden compared with activation of BRAF(V600E) alone. 26028035

2016